| Thursday, 12 November 2015 | |
| 10.00 | Welcome and Introductory Remarks |
| W. Beckmann, Bayer Technology Service, Leverkusen/D | |
| set the theme | |
| 10.10 | Following the particles on their journey from crystallizer to patient |
| C. Price, University of Strathclyde, Glasgow/UK | |
| Multiplicity of solid state forms design the form |
|
| 11.10 | Selection of solid-state forms for new chemical entities: challenges, opportunities and lessons learned |
| C. Saal, Merck KGaA, Darmstadt/D | |
| 12.00 | Hydrate phases in pharmaceutical development |
| B. Baumgartner, Sanofi-Aventis Deutschland GmbH, Frankfurt/D | |
| 12.50 | Lunch Break |
| Scientific aspects of solid-state engineering design the particle |
|
| 14.00 | Polymorphism and solvate formation – potential threats in pharmaceutical industry |
| D. Wieckhusen, Novartis Pharma AG, Basel/CH | |
| 14.50 | The role of API surface chemistry in pharmaceutical processes |
| J. Heng, Imperial College London/UK | |
| 15.40 | Solid form design & crystal habit modification: utilizing crystallographic data to guide experimental design |
| S. Chan, Novartis Pharma AG, Basel/CH | |
| 16.30 | Coffee Break |
| Molecular modelling aspects of materials science support via modelling |
|
| 16.50 | Exploring solid forms landscapes with structural informatics |
| N. Feeder, CCDC, Cambridge/UK | |
| 17.40 | Solvate formation and assessment of crystallizability and assessment of stability of amorphous materials |
| A. Florence, CMAC - University of Strathclyde, Glasgow/UK | |
| 18.30 | End-of-day-1 |
| 20.00 |
Conference Dinner at the historical Restaurant "Gerbermuehle", Gerbermuehlstrasse 105, 60594 Frankfurt |
| Friday, 13 November 2015 | |
| Formulation aspects of material science and engineering – Control of the API physical form secure the API attributes |
|
| 08.30 | Integrated crystal and particle engineering for developing pharmaceutical tablet |
| C. Sun, University of Minnesota, Minneapolis, MN/USA | |
| 09.20 | The role of particle engineering in formulation design – Link between drug substance and drug product |
| R.A. Storey, AstraZeneca R&D, Macclesfield/UK | |
| 10.10 | Coffee Break |
| paneled discussion | |
| 10.30 | Current topics of material science engineering in drug development and manufacturing |
| J.-O. Henck – C. Price – W. Beckmann – B. Baumgartner | |
| 12.00 | Lunch Break |
| Material science aspects of solid-solutions of API’s amorphous materials |
|
| 13.00 | Amorphous organic materials |
| L. Yu, University of Wisconsin, Madison, WI/USA | |
| 13.50 | Industrial perspectives of manufacturing solid dispersions as enabling technology – From early development to commercial manufacturing |
| G. Verreck, Johnson & Johnson Pharma R&D, Beerse/B | |
| 14.40 | Coffee Break |
| Control strategies of solid state form API attributes in formulation performance impact on product |
|
| 15.00 | Small-scale approaches for supporting the solid form selection |
| J. Rantanen, University of Copenhagen/DK | |
| 15.50 | What are the critical attributes of APIs which influences formulation microstructure and dominates product functionality ? |
| R. Price, University of Bath/UK | |
| 16.40 | Connecting the API solid form and particle to drug product performance |
| M. Ticehurst, Pfizer, Canterbury/UK | |
| 17.30 | End and farewell |